EconStor >
ifo Institut – Leibniz-Institut für Wirtschaftsforschung an der Universität München >
CESifo Working Papers, CESifo Group Munich >

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10419/46570
  

Full metadata record

DC FieldValueLanguage
dc.contributor.authorGrossmann, Volkeren_US
dc.date.accessioned2011-05-27en_US
dc.date.accessioned2011-06-29T11:21:32Z-
dc.date.available2011-06-29T11:21:32Z-
dc.date.issued2011en_US
dc.identifier.urihttp://hdl.handle.net/10419/46570-
dc.description.abstractThis paper examines the role of both cost-sharing schemes in health insurance systems and entry regulation for pharmaceutical R&D expenditure, drug prices, aggregate productivity, and income. The analysis suggests that both an increase in the coinsurance rate and stricter price regulations adversely affect R&D spending in the pharmaceutical sector. In contrast, entry deregulation may lead to quality-improvements of pharmaceuticals, despite reducing price-setting power of pharmaceutical companies. Extension to an endogenous growth context suggests that, when individual labor supply depends on health status, both cost-sharing and entry barriers in the pharmaceutical sector also affect aggregate productivity and wage rates.en_US
dc.language.isoengen_US
dc.publisherCESifo Münchenen_US
dc.relation.ispartofseriesCESifo working paper: Public Finance 3439en_US
dc.subject.jelI10en_US
dc.subject.jelL10en_US
dc.subject.jelO30en_US
dc.subject.ddc330en_US
dc.subject.keywordaggregate productivityen_US
dc.subject.keywordcost-sharingen_US
dc.subject.keywordentry deregulationen_US
dc.subject.keywordhealth insuranceen_US
dc.subject.keywordpharmaceutical innovationen_US
dc.subject.stwPharmazeutische Forschungen_US
dc.subject.stwForschungsfinanzierungen_US
dc.subject.stwKostenbeteiligungen_US
dc.subject.stwGesetzliche Krankenversicherungen_US
dc.subject.stwMarkteintritten_US
dc.subject.stwGesundheitsökonomiken_US
dc.subject.stwProduktivitäten_US
dc.subject.stwNeue Wachstumstheorieen_US
dc.subject.stwTheorieen_US
dc.titleDo cost-sharing and entry deregulation curb pharmaceutical Innovation?en_US
dc.typeWorking Paperen_US
dc.identifier.ppn660775697en_US
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen_US
Appears in Collections:CESifo Working Papers, CESifo Group Munich

Files in This Item:
File Description SizeFormat
660775697.pdf466.41 kBAdobe PDF
No. of Downloads: Counter Stats
Show simple item record
Download bibliographical data as: BibTeX

Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.